Kiora Pharmaceuticals, Inc. KPRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | 0.00 |
| Cost of Revenue | 3.88M | 4.04M | 3.71M | 3.72M | 3.97M |
| Gross Profit | -3.88M | -4.04M | -3.71M | -3.72M | -3.97M |
| SG&A Expenses | 5.90M | 5.87M | 5.75M | 5.61M | 5.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.77M | 9.91M | 9.46M | 9.34M | 9.52M |
| Operating Income | -9.77M | -9.91M | -9.46M | -9.34M | -9.52M |
| Income Before Tax | -12.28M | -12.47M | -12.12M | -7.11M | -9.91M |
| Income Tax Expenses | -1.29M | -1.41M | -1.28M | 1.43M | 2.08M |
| Earnings from Continuing Operations | -10.99 | -11.06 | -10.84 | -8.54 | -11.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.99M | -11.06M | -10.84M | -8.54M | -11.98M |
| EBIT | -9.77M | -9.91M | -9.46M | -9.34M | -9.52M |
| EBITDA | -9.73M | -9.87M | -9.43M | -9.32M | -9.51M |
| EPS Basic | -2.35 | -2.56 | -2.62 | -2.05 | -2.87 |
| Normalized Basic EPS | -1.20 | -1.33 | -1.31 | -1.23 | -1.27 |
| EPS Diluted | -2.36 | -2.56 | -2.62 | -2.06 | -2.87 |
| Normalized Diluted EPS | -1.20 | -1.33 | -1.31 | -1.23 | -1.27 |
| Average Basic Shares Outstanding | 19.89M | 17.70M | 16.67M | 16.71M | 16.64M |
| Average Diluted Shares Outstanding | 19.96M | 17.78M | 16.74M | 16.79M | 16.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |